It was also noticed that PGRN could increase capacity in terms of the invasiveness and metastasis of breast and ovarian cancer via the upregulation of MMP-9 and the activation of matrix metalloproteinase 2 (MMP-2) [36,89]. The gene discussed is MMP2; the disease is ovarian carcinoma.